Shire (LON:SHP)‘s stock had its “outperform” rating reissued by Royal Bank of Canada in a research report issued to clients and investors on Tuesday.
SHP has been the topic of a number of other research reports. JPMorgan Chase lowered Shire to a “neutral” rating and reduced their price target for the stock from GBX 5,000 ($71.59) to GBX 3,600 ($51.55) in a research note on Tuesday, February 20th. BNP Paribas reissued an “outperform” rating and set a GBX 4,700 ($67.30) price target on shares of Shire in a research note on Thursday, March 22nd. Morgan Stanley reduced their price target on Shire from GBX 5,700 ($81.62) to GBX 4,700 ($67.30) and set an “overweight” rating on the stock in a research note on Monday, March 19th. Citigroup reissued a “buy” rating and set a GBX 5,500 ($78.75) price target on shares of Shire in a research note on Friday, January 5th. Finally, Goldman Sachs reissued a “conviction-buy” rating and set a GBX 4,600 ($65.86) price target on shares of Shire in a research note on Monday, March 26th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of GBX 4,550.80 ($65.16).
SHP stock opened at GBX 3,617 ($51.79) on Tuesday. Shire has a 1 year low of GBX 2,940.50 ($42.10) and a 1 year high of GBX 5,021 ($71.89).
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/17/shire-shp-stock-rating-reaffirmed-by-royal-bank-of-canada.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.